ArticleCancer2018
Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.
Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolic syndrome is associated with breast cancer mortality: A systematic review and meta-analysis.Journal of internal medicine · 2025Pooled it
- Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment.JAMA oncology · 2025Article
- Challenges and opportunities for improving cardiovascular health in women with breast cancer: a review.Cardio-oncology (London, England) · 2025Review
- Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Cardiovascular Disease Incidence and Cardiovascular Health Among Diverse Women With Breast and Gynecologic Cancers.Oncology nursing forum · 2024Article
- Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.Cardio-oncology (London, England) · 2024Article
- Cardiovascular disease in thymic cancer patients.Frontiers in cardiovascular medicine · 2024Article
- Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study.BMC cancer · 2023Article
- Chemotherapeutic drug screening in 3D-Bioengineered human myobundles provides insight into taxane-induced myotoxicities.iScience · 2022Article
- Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women's Health Initiative.BMC women's health · 2022Article
- A review of research on the intersection between breast cancer and cardiovascular research in the Women's Health Initiative (WHI).Frontiers in oncology · 2022Review
- The Importance of Primary Care in Cardio-Oncology.Current treatment options in oncology · 2021Review
- Cardiac morbidity & mortality in patients with breast cancer: A review.The Indian journal of medical research · 2021Review
- Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women.Breast cancer research and treatment · 2021Article
- Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.BMC cancer · 2021Article
- Article
- Hyperinsulinemia in Obesity, Inflammation, and Cancer.Diabetes & metabolism journal · 2021Review
- Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.Cancer · 2021Article
- Impact of cholesterol-pathways on breast cancer development, a metabolic landscape.Journal of Cancer · 2021Review
- Construction of a Prognostic Risk Prediction Model for Obesity Combined With Breast Cancer.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundFew studies have examined the relationship between cardiometabolic risk factors linked to metabolic syndrome and mortality among women with breast cancer.
methodsWe used the Women's Health Initiative to evaluate the relationship between cardiometabolic risk factors, including waist circumference (WC), blood pressure, cholesterol level, and presence of type 2 diabetes, and their relation with death from breast cancer, cardiovascular disease (CVD), and other causes among 8641 women with local or regional stage invasive breast cancer. Cox proportional hazards models were used to estimate hazard ratios, and 95% confidence intervals, adjusted for important predictors of survival.
resultsAfter a median of 11.3 years, there were 2181 total deaths, 619 (28.4%) of which were due to breast cancer. Most participants (55.7%) had at least 2 cardiometabolic risk factors, and 4.9% had 3 or 4. Having a larger number of risk factors was associated with higher risk of CVD and other-cause mortality (P trend < .001 for both), but not with breast cancer mortality (P trend = .86). Increased WC was associated with a higher risk of CVD (hazard ratio [HR], 1.28; 95% confidence interval [CI], 1.05-1.57) and other-cause mortality (HR, 1.32; 95% CI, 1.16-1.49) and only with a small and nonsignificant higher risk of breast cancer mortality (HR, 1.19; 95% CI, 0.93-1.52). The results did not differ in analyses stratified by race, hormone receptor status, or after an analysis of cases diagnosed within 5 years after baseline.
conclusionsAmong women with early stage breast cancer, cardiometabolic risk factors are significantly associated with cardiovascular and other-cause mortality, but not breast cancer mortality. Cancer 2018;124:1798-807. © 2018 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.